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Background: The aim of this study was to probe cardiac complications, including heart-rate control, in a mouse
model of type-2 diabetes. Heart-rate development in diabetic patients is not straight forward: In general, patients
with diabetes have faster heart rates compared to non-diabetic individuals, yet diabetic patients are frequently
found among patients treated for slow heart rates. Hence, we hypothesized that sinoatrial node (SAN) dysfunction
could contribute to our understanding of the mechanism behind this conundrum and the consequences thereof.
Methods: Cardiac hemodynamic and electrophysiological characteristics were investigated in diabetic db/db and
control db/+ mice.
Results: We found improved contractile function and impaired filling dynamics of the heart in db/db mice, relative
to db/+ controls. Electrophysiologically, we observed comparable heart rates in the two mouse groups, but SAN
recovery time was prolonged in diabetic mice. Adrenoreceptor stimulation increased heart rate in all mice and
elicited cardiac arrhythmias in db/db mice only. The arrhythmias emanated from the SAN and were characterized
by large RR fluctuations. Moreover, nerve density was reduced in the SAN region.
Conclusions: Enhanced systolic function and reduced diastolic function indicates early ventricular remodeling in
obese and diabetic mice. They have SAN dysfunction, and adrenoreceptor stimulation triggers cardiac arrhythmia
originating in the SAN. Thus, dysfunction of the intrinsic cardiac pacemaker and remodeling of the autonomic
nervous system may conspire to increase cardiac mortality in diabetic patients.
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Diabetes mellitus is a serious public health concern and
the global prevalence was estimated to be 2.8% in 2000
rising to 4.4% in 2030 [1]. The incidence of cardiovas-
cular disease is higher among diabetic patients [2], and
they often die from cardiovascular complications [3].
Coronary artery disease secondary to atherosclerosis
account for a large fraction of the comorbidity, likely
underlying the reports of myocardial infarction as the
main cause of mortality in diabetic patients [3]. The vast
majority of diabetic patients have type-2 diabetes melli-
tus (T2DM), characterized by obesity, insulin resistance
and very high blood glucose levels.* Correspondence: mbthom@sund.ku.dk
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article, unless otherwise stated.Elevated resting heart rate is associated with an in-
creased risk of cardiovascular complications and sudden
cardiac death in the general population and in T2DM
patients [4-6]. Conversely, in patient groups with elec-
tronic cardiac pacemakers due to slow heart rates, there
is a statistically significant overrepresentation of diabetic
patients, suggesting diabetes-induced impairment of the
endogenous, natural pacemaker of the heart [7-9]. Sick
sinus node syndrome is associated with T2DM in case
reports only [10]. Reports of impaired atrio-ventricular
node in diabetic patients [11,12] supports the clinical
observation that the cardiac conduction system, espe-
cially the function of the nodes, are compromised in
T2DM. Hence, there are strong clinical indications of
altered sino-atrial node (SAN) function in T2DM and
that this could contribute to the increased cardiovascular
mortality in this large patient population.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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lacks the hypothalamic leptin regulation resulting in de-
velopment of obesity and severe T2DM [13]. The model
shows age-dependent progression of metabolic abnorma-
lities that mimics the pathogenesis of T2DM in humans,
including early insulin resistance and hyperinsulinemia at
mouse age 6–12 weeks, followed by an insulin-secretory
defect and hypoinsulinemia after 12 weeks [14]. Previous
experimental studies related to effects of diabetes on SAN
function have been conducted primarily in T1DM animal
models [15-17], which lack the metabolic complexity of
T2DM. Reports from heart rate recordings in conscious
or anesthetized db/db mice with T2DM have revealed
profound inconsistencies in results with examples of faster
[18], slower [19,20] and comparable [21-23] resting heart
rates. The clinical finding of SAN dysfunction in a small
subset of diabetic patients and the discrepancies in the ex-
perimental findings of heart rate in db/db mice imply that
this mouse model may constitute a unique tool for stu-
dying the effects of diabetes on SAN function.
In the present study, we hypothesized that db/db mice
have a concealed SAN dysfunction in vivo that can be
unmasked by the appropriate stress. We probed and chal-
lenged SAN function to elicit changes in heart rate and
heart rate instability compatible with the clinical obser-
vations of augmented cardiovascular death. At basal con-
ditions, heart rate is not different in anesthetized db/db
mice; however, upon a challenge with β-adrenoreceptor
stimulation we exposed pronounced SAN dysfunction
inducing prominent heart-rate fluctuations. Invasive elec-
trophysiological studies showed a prolonged sinus node
recovery time and immunoblots of SAN tissue identified
reduced density of autonomic nerve endings.Methods
Animals
Experiments were performed using male leptin-receptor
deficient db/db mice (C57BL/KS-leprdb/leprdb) and lean
control heterozygote db/+mice (C57BL/KS-leprdb/lepr+),
aged 14–16 weeks. Animals were purchased from Taconic
(Denmark) and housed in a specific pathogen free facility
with ad libitum access to water and standard chow food
in a room with a 12-h light/dark schedule and an ambient
temperature of 22°C. Mice were anesthetized in 1.5-2%
isoflurane in 100% O2. Body temperature was constantly
monitored and kept at 37 ± 0.5°C. Blood glucose levels
were determined from the tail vein as the mean of 2 con-
secutive measurements by a Microdot glucometer (Kacey
Diagnostics, USA). Body weight was determined prior to
each investigation. At the end of experiments, euthanasia
was achieved by cervical dislocation. A total of 12 db/db
mice and 12 db/+mice were used for this study. The study
conformed to the Principles of laboratory animal care(National Institutes of Health, revised 1996) and was ap-
proved by the national ethics committee.
Echocardiography
Transthoracic echocardiography was performed with a
linear 15–45 MHz transducer (Vevo 770, VisualSonics,
Canada), as previously described [24]. Inner diameter
of the left ventricle (LVID) and LV wall thicknesses
(LVWT) in diastole and systole were measured in M
mode at the maximal and minimal cross sectional dia-
meter in a heart cycle, respectively, at the level of the
Papillary muscles and averaged from parasternal long
axis and short axis view. Left ventricular length from
aortic valve to LV endocardial apex was measured in the
parasternal long axis view. Left ventricular end-diastolic
volume (LVEDV) and end-systolic volume (LVESV) were
calculated as LVID3*{7/(2.4 + LVID)} in diastole and sys-
tole, respectively. Stroke volume (SV = LVEDV-LVESV)
and ejection fraction (EF = SV/LVEDV) were calculated.
Subsequently, LV filling properties were evaluated by
pulsed wave Doppler imaging. Recordings were made at
the tips of the mitral-valve leaflets in the apical four-
chamber view. Peak early (E) and late (A) mitral inflow
velocities, deceleration time (DT) of early filling and
isovolumetric relaxation time (IVRT) and contraction
time (IVCT) were measured as described previously
[25]. Three measurements from consecutive heart cycles
were obtained and averaged in each mouse. Six mice of
each genotype were used in the echocardiographic study.
Electrocardiography
A 6-lead surface electrocardiogram (ECG) was recorded
(LabChart 8, ADInstruments, Australia) using subcuta-
neous needle electrodes. Signals were recorded at 4 kHz
and filtered using a low-pass setting of 1 kHz and a
high-pass setting of 0.3 Hz. After 10 min baseline, iso-
prenaline (2 μg/g) was injected intraperitoneally. Ave-
raged signal ECGs were generated by aligning R waves
of >200 complexes from lead I and analyzed manually as
previously described in detail [26]. The dominant cardiac
depolarization axis was determined from vectorcardio-
graphy from the frontal plane as the angle between lead
I and the largest amplitude vector during the QRS com-
plex. Mice were challenged with a β-adrenoreceptor
agonist, isoprenaline, administered intraperitoneally at a
dose of 2 μg/g body weight as previously described [24].
Isoprenaline (Sigma-Aldrich, St. Louis, MO) was dis-
solved and diluted in saline on the day of experiment.
In order to quantify fluctuation in RR intervals and SAN
arrhythmias, we used the algorithms of heart-rate varia-
bility (HRV). Consecutive RR intervals were determined
in comparable time epochs of 10 minutes at baseline and
at 5–10 minutes after β-adrenoreceptor stimulation, and
the following parameters were calculated [27]: standard
Table 1 Characteristics of the control (db/+) and diabetic
(db/db) mice
db/+ (n = 11) db/db (n = 9)
Body weight, g 26 ± 0.5 39 ± 1.5*
Heart weight, mg 171 ± 5.5 145 ± 4.5*
Tibia length, mm 21 ± 0.3 20 ± 0.4
Non-fasting blood glucose, mg/dL 190 ± 13 526 ± 26*
Fasting blood glucose, mg/dL 76 ± 98 474 ± 42*
*, P < 0.05, Student’s t-test.
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the difference between successive RR intervals (SDΔRR),
percentage of normal consecutive RR intervals differing
by >6 ms (pRR6, see reference [27]), normalized power
contained within the low frequency range (0.15-1.5 Hz, LF
power), and normalized power contained within the high
frequency range (1.5-5.0 Hz, HF power). The presence of
induced SAN arrhythmia in a mouse was acknowledged
if SDRR, SDΔRR or pRR6 increased by >100% following
β-adrenoreceptor stimulation.
Twelve mice of each genotype were used in the electro-
cardiographic study, half of which had been used prior in
the echocardiographic study. Three db/db mice and one
db/+mouse died within a 12-hour period after recovery
from the electrocardiographic study; the remaining 9 db/db
and 11 db/+mice were used subsequently for an invasive
electrophysiological study.
Intracardiac pacing
Mice were fasted for 16 hours prior to intracardiac pacing
to challenge the mice with hypoglycemia. During anes-
thesia, a 1.1 F pacing catheter (EPR-800, ADInstruments)
was advanced into the LV through a small incision in the
right common carotid artery. Atria and ventricles were
paced at 1.5 and 2 times capture threshold amplitudes, re-
spectively. Sinus node recovery time (SNRT) was mea-
sured twice after delivering an atrial pacing train with a
cycle length of 100 ms (600 beats per minute) for 15 se-
conds, and defined as the duration between the last pacing
stimuli and the onset of the first spontaneous P wave.
Rate-corrected SNRT (CSNRT) was calculated by sub-
tracting the baseline, sinus-node controlled PP interval
length from the SNRT. Wenckebach periodicity was de-
termined by progressively shortening the paced cycle
length and defined as the shortest cycle length maintain-
ing a 1:1 conduction between the atrium and ventricles.
Ventricular effective refractory period (VERP) was de-
termined by applying 9 paced ventricular beats (9xS1) at a
cycle length of 100 ms followed by a single extra-stimulus
(S2) that was sequentially increased in 1 ms steps until
capture. VERP was defined as the longest S1-S2 interval
that did not result in ventricular capture. Inducibility of
arrhythmia was tested by a pacing protocol consisting of
9xS1 at the cycle length of 100 ms followed by 6xS2 [24].
Ventricular tachycardia (VT) was defined as ≥4 sponta-
neous consecutive beats following the last captured S2. If
VT was induced, the stimulation protocol was repeated
twice to ascertain reproducibility [24].
Immunoblotting
The right atria were homogenized in ice-cold RIPA buffer
supplemented with protease inhibitors (AEBSF, 2 mM;
aprotinin, 0.3 μM; bestatin, 130 μM; E-64, 14 μM; leupep-
tin, 1 μM) using the Precellys system (Bertin Technologies,France). Proteins (10 μg) were separated on a 4-15%
SDS-PAGE (Biorad, Denmark) and blotted onto hybond-P
polyvinylidene fluoride transfer membranes (Amersham
Biosciences, Denmark). Membranes were incubated with
anti-synaptophysin antibody (0.2 μg/ml, Santa Cruz
Biotechnology, USA). Synaptophysin is essential for sy-
naptic vesicle regulation neurons and is a marker of nerve
synapses. Immunoreactive proteins were detected by HRP-
linked donkey anti-rabbit antibody (8 ng/ml, Jackson Immu-
nosearch Laboratories, UK). Membranes were stripped and
re-probed with anti-actin antibody (MAB1501, Millipore,
Denmark). Protein band density was quantified as a
Gaussian densiometric trace on the exposed films and
processed equally. Immunoblotting was repeated three
times and the average ratio of Synaptophysin/Actin bands
density was calculated for each sample and used for the
comparison between groups.
Statistical analysis
Data is represented as mean ± SEM and the number of
observations (n) is indicated on each figure. Two-tailed
Student’s t-test and two-way ANOVA followed by post-
hoc Bonferroni t-test were used for comparison of 2 or
more groups, respectively. Fisher’s exact test was employed
to compare the occurrence of arrhythmias. P-values <0.05
were considered statistically significant.
Results
Improved systolic function and reduced diastolic function
in diabetic mice
At the age of 14–16 weeks, db/db mice exhibited pro-
nounced hyperglycemia and larger body weights (Table 1).
Wet cardiac weights were lower in db/db mice (Table 1).
To evaluate LV structure and mechanical function cardiac
imaging was performed in the intact animal (Figure 1A).
We noted no difference in the LV wall thickness (db/+:
0.92 ± 0.06 versus db/db: 0.86 ± 0.03 mm in diastole; n = 6,
P > 0.05); however, db/db mice have significantly shorter
LV length than db/+mice (db/+: 7.3 ± 0.1 versus db/db:
6.8 ± 0.2 mm in diastole; n = 6, P < 0.05).
A hypercontractile systolic function in db/db mice was
indicated by a greater fractional shortening (Figure 1B)
and larger ejection fraction (db/+: 67 ± 2 versus db/db:
Figure 1 Echocardiographic assessment of left ventricular structure and mechanical function. A, Representative M-mode echocardio-
graphic images of the left ventricle (LV) from anesthetized mice. LV cav: cavity; LVAW: anterior wall; LVPW: posterior wall. B, Fractional shortening
of the LV. C, Left panel: Exemplary transmitral velocity-time curves with positive peaks representing flow velocities during passive early filling (E)
and atrial contraction (A). Vertical lines indicate the demarcation of ejection time (ET), deceleration time (DT), isovolumetric relaxation time (IVRT)
and isovolumetric contraction time (IVCT). Right panel: Deceleration phase of the E peak. *, P < 0.05, Student’s t-test.
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pler analysis of mitral inflow, where isovolumetric contrac-
tion time (IVCT) tended to be shorter in db/db mice (db/+:
11.4 ± 0.3 versus db/db: 10.7 ± 0.2 ms; n = 6, P = 0.07),
suggesting improved systolic function in db/db mice. In
contrast, isovolumetric relaxation time (IVRT) was indistin-
guishable (db/+: 22.2 ± 3.5 versus db/db: 20.8 ± 2.7 ms;
n = 6, P > 0.05). Similarly, analysis of Doppler-derived peak
velocities during early (E) ventricular filling and atrial (A)
contraction (Figure 1C, left panel) showed no difference
between genotypes (E/A ratio in db/+: 1.59 ± 0.04 versus
db/db 1.88 ± 0.02; n = 6, P > 0.05); however, deceleration
time of early peak flow (DT) was prolonged by 55% in
db/db mice suggesting a diastolic insufficiency in these
mice (Figure 1C). Taken together, a shorter heart, improved
systolic function and reduced diastolic function indicate
early ventricular remodeling in db/db mice.
Unexpected electrophysiological phenotype in db/+ mice
Next, we evaluated electrophysiological function by ana-
lyzing surface ECG in anesthetized animals (Figure 2).
The cardiac QRS axis was normal and uniform in most
db/db mice (75 ± 8°; n = 12); however in db/+mice we
observed dominant axes in all 4 quadrants of the vector-
cardiogram (Figure 2A). On average, the cardiac axis in
db/+mice was 3 ± 23° (n = 12; P < 0.05 versus db/db),
where the large standard error reflects the very heteroge-
neous group of mice. Indeed, we excluded 3 db/+micefrom further electrocardiographic comparison due to in-
comparable ECGs (cardiac axes in these mice were −154°,
−28° and +125°, respectively). A representative raw ECG
trace in a db/db mouse and an example with comparable
ECG morphology from a db/+mouse, are depicted on
Figure 2B.
Analysis of averaged ECG signals (Figure 2C), showed
no difference in the duration of RR, PQ, QRS and QT in-
tervals (Figure 2D). Heart rates were 485 ± 20 and 465 ±
13 beats per minute in db/+ and db/db mice, respectively
(P > 0.05). The amplitude of the J wave was comparable in
two groups of mice (db/+: −51 ± 8 versus db/db: −47 ±
9 μV; P > 0.05). The amplitude of T wave could be reliably
measured in 11/12 db/db mice but only in 4/9 control
mice due to highly variable cardiac axes and consequently
heterogeneous ECG morphologies. Based on this limited
number of observations, the peak of T wave was more
negative in the db/db versus db/+mice (db/+: −30 ± 3 ver-
sus db/db: −55 ± 6 μV; P < 0.05).
Compromised sinoatrial function in diabetic mice
Within the individual mouse, the ECG complexes were
comparable and very regular at baseline in both groups
of mice (Figure 2B), revealing no indications of SAN
dysfunction. β-Adrenoreceptor stimulation significantly
increased heart rate in both db/+ and db/db mice in a
comparable manner (Figure 3A and B; mean heart rate
increase were db/+: 28 ± 5 versus db/db: 32 ± 4% increase;
Figure 2 Electrophysiological function. A, Cardiac axis in individual mice. B, Raw ECG traces from lead I in db/+ and db/db mice. C, Exemplary
averaged ECG complex in a db/db mouse shown on the enlarged scale. D, No statistical difference of averaged ECG intervals was found between
db/+ and db/db mice.
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stant after isoprenaline administration in the control
mouse (Figure 3A and C); however, the RR tachogram in
the db/db mouse (Figure 3B and D) showed a large scatter
of inter-beat intervals 5–10 minutes after β-adrenorecep-
tor challenge. The ECG in the Figure 3F clearly shows that
the arrhythmia originated from the SAN as the observed
RR fluctuations were accompanied by preserved P waves
and PQ intervals. The histograms shown in Figure 3G and
H show that the distributions of inter-beat intervals were
comparable in two representative mice at baseline. After
challenge with isoprenaline, the range of RR intervals in
the control mouse remained narrow (range: 105–113 ms);
however, in contrast, db/db mice show a wide spread of
RR intervals (range: 85 to 216 ms). In particular, we re-
corded multiple late beats, in the range of 120–220 ms,
(inset on the Figure 3H) which were never seen in any
control mice.
To quantify these SAN arrhythmias, we took advantage
of standard HRV algorithms. Before β-adrenoreceptor
stimulation, RR, SDRR and SDΔRR were indistinguishable
in db/+ and db/db mice (Figure 4, Table 2). After β-adre-
noreceptor stimulation, these HRV parameters remained
unchanged in control mice, but increased dramatically in
db/db mice (Figure 4B and C). Altogether, episodes of
SAN arrhythmia were observed in 7/12 db/db mice but in
none of the control animals (P < 0.05). During recoveryfrom the electrophysiological study, 3 db/db mice and 1
db/+mouse died. We have no ECG record of the events.
In order to challenge the mice with relative hypo-
glycemia, we subjected the mice to 16-hours fasting
which decreased blood glucose concentration in both
db/+ and db/db (Table 1). Reduction of glucose concen-
tration had no effect on ECG morphology, but we noted
a modest but significant increase of RR intervals as a
consequence of fasting (Table 2). Hypoglycemia resulted
in dramatic increases of SDΔRR and pRR6 in db/db
mice only (Table 2). Spectral analysis of HRV showed no
difference in autonomic control of heart rate at baseline
during anesthesia (Table 2).
To determine whether the origin of the cardiac
arrhythmia was indeed the SAN, we evaluated the SAN
directly in an invasive electrophysiological study. Sinus
node recovery time was 139 ± 3.8 ms in db/+mice, but de-
layed to 170 ± 13 ms in db/db mice (P < 0.05, Figure 5A).
Sinus node recovery time corrected for baseline heart rate
(CSNRT) also showed delayed recovery time in db/db mice
(Figure 5B), indicating reduced SAN automaticity. Whereas
db/db mice exhibited impaired SAN function, they show
no change in AV Wenckebach periodicity (Figure 5C), a
finding supported by preserved PQ intervals (Figure 2C),
or VERP (Figure 5D). Susceptibility to pacing-induced ven-
tricular arrhythmias were comparable in the two groups of
mice (db/+: 3/11 versus db/db: 1/9 mice; P > 0.05).
Figure 3 Dynamics of RR interval upon β-adreneroceptor stimulation. A, B Exemplary tachograms of RR intervals at baseline and during
isoprenaline challenge (arrows indicate IP administration of isoprenaline). C, D The same two tachograms at enlarged scales, showing RR intervals
during 1 minute (8 to 9 minutes after administration of isoprenaline). E, F Two-second ECG traces from the same mice, around time point 8:40
after administration of isoprenaline. G, H Histograms of RR intervals constructed by analysis of 3 minutes ECG recordings before and after
isoprenaline administration.
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db/db mice
In vivo, pacemaking activity of the SA node is constantly
modulated by an input from autonomic nervous system.
Prolonged CSNRT in db/db mice would suggest intrinsic
nodal abnormalities, but we suspected that SA nodal
dysfunction may be extrinsic as it is not evident at the
baseline ECG but is unmasked by adrenergic stimula-
tion. Impaired autonomic modulation may be attributed
to nerve rarefaction so we harvested right atrial tissue
including SAN to quantify expression of synaptophysin.Synaptophysin migrated as a single band, at the expected
molecular weight of approximately 40 kDa (Figure 6A).
On average, db/db mice showed a 29% lower synap-
tophysin/actin ratio, suggesting diminished autonomic
nerve density as a potential modulator of the intrinsic
SAN dysfunction.
Discussion
Increased heart rate is the common finding in patients
with T2DM; however, diabetes is also associated with in-
creased susceptibility to slow heart rates [7,12] and with
Figure 4 Quantification of RR fluctuations. A Mean RR interval during 3-min periods before and after isoprenaline injection. B Standard deviation
of the same RR intervals. C Standard deviation of the differences between consecutive RR intervals. *, P < 0.05, Repeated-measures two-way ANOVA
followed by post-hoc Bonferroni test.
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gesting defective pacemaking function in some of these
patients. Altered heart rate may contribute to excess car-
diovascular mortality in T2DM [4,5] and it is important to
unravel how SAN dysfunction is triggered and to find
ways to prevent or treat it. In addition, clinical risk stratifi-
cation of patients using heart rate and HRV may be misin-
terpreted in settings of SAN dysfunction and potentially
in T2DM. Our data provides experimental evidence that
T2DM complicated by obesity, adversely affects SAN
function. In vivo, electrophysiological testing in db/dbTable 2 Heart-rate variability parameters obtained in
anesthetized control (db/+) and diabetic (db/db) mice
before and after 16 hours fasting
Db/+, fed Db/db, fed Db/+, fasted Db/db, fasted
RR, ms 124 ± 4 131 ± 3 137 ± 4 † 154 ± 4*†
HR, bpm 483 ± 17 458 ± 12 438 ± 11 † 390 ± 10*†
SDRR, ms 4.4 ± 1.0 5.0 ± 0.9 5.3 ± 0.8 6.0 ± 1.6
SDΔRR, ms 2.1 ± 0.3 3.2 ± 0.6 2.8 ± 0.6 4.7 ± 0.7*
pRR6,% 3 ± 4 11 ± 5a 8 ± 3 22 ± 6*
LF Power, μs2 0.9 ± 0.2 0.9 ± 0.4 1.0 ± 0.4 2.5 ± 1.0
HF Power, μs2 2.4 ± 0.6 7.9 ± 3.8 6.1 ± 3.4 15.4 ± 4.3a
LF Power, % 32 ± 4 17 ± 4 17 ± 4 15 ± 5
HF Power, % 67 ± 4 84 ± 4 84 ± 4 86 ± 5
LF/HF 55 ± 11 25 ± 10 24 ± 9 19 ± 4
n 12 12 10 9
Abbreviations: HR (bpm) heart rate in beats per minute, SDRR standard
deviation of RR intervals, SDΔRR standard deviation of the difference between
successive RR intervals, pRR6 percentage of normal consecutive RR intervals
differing by >6 ms, LF power absolute and normalized power contained within
the low frequency range (0.15-1.5 Hz), HF power absolute and normalized
power contained within the high frequency range (1.5-5.0 Hz). See reference
[27]. Two-way ANOVA with a post hoc Bonferroni t test when appropriate.
*, P < 0.05 versus db/+mice; †, P < 0.05 versus fed mice of the same genotype;
a, P = 0.063 versus db/+. One mouse was excluded from the db/+, fasted group
due to technical difficulties with anesthesia.mice revealed substantial prolongation of corrected SAN
recovery time, indicating abnormal pacemaking function.
The defect in the SAN becomes manifest during fasting
and pathologic during stress test with isoprenaline, where
db/db mice exhibited SAN arrhythmia resulting in a pro-
found fluctuation of RR intervals.
Diabetic mice have SAN dysfunction
Luo and colleagues recently showed that mice with
streptozotocin-induced T1DM also develop SAN dysfunc-
tion, which manifested as a reduced resting heart rate,
prolonged CSNRT and an attenuated chronotropic re-
sponse to isoprenaline in isolated, perfused hearts [15].
Rats with streptozotocin-induced T1DM also show signs
of nodal abnormalities, such as bradycardia and prolonga-
tion of the SAN action potential [16,29,30]. In addition, an
early experimental study of effects of diabetes on conduc-
tion system also demonstrated prolonged CSNRT in atrial
preparations from alloxan-treated rabbits [17]. With the
present study, we show that SAN dysfunction also is
present in models of T2DM.
In the present study, the chronotropic response to iso-
prenaline was comparable in db/db and db/+mice. Heart
rate reached a maximal level 30–40 sec after the injection
(Figure 3), but surprisingly, the arrhythmias in db/db mice
were delayed till 5–10 minutes after adrenergic stimula-
tion. Heart rate is determined by the intrinsic pacemaking
activity of the SAN; however, it is modulated by external
factors such as autonomic function, hemodynamic load
and metabolic status [31,32]. The db/db mice show
complex cardioregulatory autonomic dysfunction, hyper-
tension and metabolic disturbances [18], which may con-
tribute to or underlie the observed SAN arrhythmias. We
found that the nodal defects in db/db mice coincide with
a relative denervation of SAN as implicated by a 29%
lower expression of synaptophysin in right atrial tissue
Figure 5 Invasive electrophysiological study. A, Measurements of sinus node recovery time (SNRT): exemplary ECG recordings obtained
during atrial pacing at 100 ms paced cycle length and immediately upon termination of electrical stimulation. Triangles indicate stimulus artifact.
Note delayed recovery of sinus rhythm in the db/db mouse. B, Corrected SNRT (CSNRT) was obtained by subtracting the sinus cycle length from
the SNRT and was significantly prolonged in db/db mice. C, Atrioventricular (AV) Wenckebach periodicity, measured as the shortest paced cycle
length allowing conduction of electrical impulse from atria to ventricles, remained unchanged in db/db mice. D, Ventricular effective refractory
period (VERP), measured by extra-stimuli technique as the longest paced cycle length that did not elicit a propagating response, was indistinguishable
in db/+ and db/db mice. *, P < 0.05, Student’s t-test. Number of animals is indicated in parentheses. The SNRT and AV Wenckebach period were not
obtained in 1 db/+ and 1 db/db mouse, respectively, due to technical difficulties.
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mal model of diabetic cardiac autonomic neuropathy [33].
In the present study, we have not proven a causal relation-
ship between reduced nerve density in pacemaker tissue
of db/db mice and abnormal heart rate fluctuations; how-
ever, since SAN arrhythmia was not present at the resting
conditions, but developed as a consequence of a persistent
autonomic challenge, it strongly suggest a contribution of
defective autonomic SAN regulation and potentially
neurotransmitter depletion in diabetes-related nodal dys-
function. This is supported by the clinical finding of car-
diovascular autonomic neuropathy in up to 90% patients
with advanced diabetes [34], and reports of compromised
neurotransmitter handling in cardiac tissue from diabetic
patients [35-37].
Isoprenaline is a mixed β-adrenergic receptor agonist
that besides it’s positive chronotropic response via β1-ad-
renergic receptors in the SAN will elicit a β2-mediated
relaxation of arterioles, resulting in a reduction of the pe-
ripheral blood pressure. Activation of the baroreceptorswould augment the activity of the sympathetic nerves to
the heart and reduce vagal activity. Spontaneous barore-
flex sensitivity is comparable in db/db and db/+mice [19],
and it is not affected by the presence of diabetes in pa-
tients with coronary artery disease [38]. Notwithstanding,
cardiac autonomic neuropathy and vagal remodeling is a
serious complication of diabetes; however, animal studies
have shown that cardiac cholinergic neurons and atrial
sensitivity to acetylcholine are not lost [39]. In the present
study, we have not monitored peripheral blood pressure
and cannot comment on the potential impact of baro-
receptor sensitivity or cardiac autonomic neuropathy on
the observed RR fluctuations in db/db mice.
The mechanisms behind the observed SAN dysfunc-
tion remain elusive. Sinoatrial conduction time may be
impaired due to lipid accumulation and lipotoxicity in
hyperglycemic diabetes [40]. In addition, rats offered
high-glucose drinking water for 8 weeks develop dys-
functional SAN and perinodal fat depositions, potentially
explaining the elevated RR fluctuations in the animals
Figure 6 Synaptophysin expression in right atria tissue.
A, Exemplary immunoblots. B, Averaged ratio of synaptophysin/actin
band densities (5 hearts x 3 independent immunoblotting experiments).
*, P < 0.05, Student’s t-test.
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replacement via chronic activation of the calcium/
calmodulin-dependent protein kinase II (CaMKII) has
been suggested to contribute to increased sudden death in
diabetic patients [15]. Moreover, hyperglycemia directly
activates CaMKII in ventricular cardiomyocytes thereby
aggravating calcium-dependent cardiac arrhythmias [42].
In the isoprenaline experiments of the present study, rela-
tive hyperglycemia and activation of the β-adrenergic sig-
naling pathway may have conspired to activate CaMKII in
the db/db SAN [43] thereby facilitating SAN arrhythmias.
In the invasive studies, relative hypoglycemia and absent
β-adrenoceptor stimulation may explain why overt RR
fluctuations were not observed.
Early hemodynamic remodeling in diabetic mice
Echocardiographic imaging of diastolic function in
db/+mice showed transmitral flow velocities comparable
to earlier reports in wild-type mice [25]. Cardiac imaging
in db/db mice showed diastolic insufficiency and increased
systolic function. These alterations are similar to findings
from patients with insulin resistance and early-stage
diabetes that show diastolic dysfunction, but no signs of
systolic impairment or structural changes [44,45]. Thesmaller weight of the db/db hearts is in part explained bý
the shorter LV parasternal length. It is tempting to specu-
late that that the shorter LV length in db/db mice contri-
butes to improved systolic function via a reduction of wall
stress, according to La Place’s law. Several other studies
have used cardiac imaging to evaluate cardiac structure
and mechanical function in db/db model. It appears
that no consensus is established as some reports show car-
diac hypertrophy with systolic and diastolic dysfunction
[46,47], whereas others reported no change in cardiac
function [20]. Discrepancies between some reports may be
due to the duration and the type of diabetes, background
mouse strain, gender and anesthesia.
The present study was performed in leptin-receptor defi-
cient mice characterized by high levels of circulating leptin.
Leptin-deficient mice develop obesity and cardiac remo-
deling which is completely reversed by leptin infusion,
suggesting that leptin itself has cardiac anti-hypertrophic
bioactivity [22]. Notwithstanding, pro-hypertrophic effects
of leptin has also been shown, primarily in vitro [48-50],
but also in vivo [51]. It is not known whether high plasma
levels of leptin, obesity or diabetes per se is the culprit for
inducing the observed SAN dysfunction or the reduced
autonomic nerve density.
Electrocardiographic abnormalities in db/+mice
We chose to use the genetically comparable, lean, non-
diabetic db/+ mice as controls in the present study, ra-
ther than +/+mice. The variability in the cardiac axis
among the individual db/+mice in the present study is
surprisingly large (Figure 2A). The cardiac QRS axis is
the general direction of the depolarization wave front in
the ventricles, and would normally lie between 0 and
120° when the impulse spread from the AV node
throughout the heart. Left and right sided axis deviation
from the normal range are usually contributed to left or
right ventricular hypertrophy, respectively, or a conduc-
tion defect. Excessive abdominal fat, as is often seen in
T2DM patients, can displace the diaphragm and angle
the heart towards an apparent left axis deviation, when
the patient is in a supine position; however, this cannot
be the underlying reason for the axis variability in the
lean controls. It is beyond the scope of the present study
to determine the reason for the highly inconsistent and
abnormal cardiac axis among db/+mice, but it raises a
serious concern regarding whether the db/+mouse is an
appropriate control for the db/db mouse in studies of
cardiac complications in the setting of diabetes.
Clinical implications
The association between diabetes and defective pacemaker
function in the heart may contribute to the increased car-
diovascular mortality in the diabetic population. As dia-
betic patients are overrepresented in the population with
Soltysinska et al. Cardiovascular Diabetology 2014, 13:122 Page 10 of 11
http://www.cardiab.com/content/13/1/122electronic pacemakers treating intrinsically slow heart
rates [7], experimental, translational and clinical studies of
SAN function on a diabetic background are relevant. Dia-
betic patients may be at increased risk of life-threatening
cardiac arrhythmias when exposed to periods of increased
adrenergic drive in physical exercise or emotional stress.
Future clinical studies should be designed to verify if dia-
betes constitutes a risk factor for development of SAN
dysfunction and if so whether it’s early detection and treat-
ment could lower mortality in diabetic patients.Limitations
The present study offers little insight into the time course
of diabetes-related SAN dysfunction as we evaluated mice
only at one time point. Synaptophysin is a general marker
of nerve synapses, and we have not established a causal
mechanism between synaptophysin downregulation and
SAN dysfunction. Db/db mice are obese, hyperglycemic
and diabetic and which metabolic alteration is the prima-
rily driver for development of SAN dysfunction remains
to be determined. Anesthesia reduces the power of HRV
and conclusions from the frequency domain analysis
should be drawn with caution [52]. Finally, limitations
have to be considered when extrapolating experimental
data from small animals to diabetic patients.Conclusions
Sinoatrial node dysfunction, characterized by prolonged
CSNRT and autonomic nerve rarefaction, is present in
mice with diabetes. β-Adrenoreceptor stimulation triggers
cardiac arrhythmia originating in the SAN. Thus, dysfunc-
tion of the intrinsic cardiac pacemaker and remodeling of
the autonomic nervous system may conspire to increase
cardiac mortality in diabetic patients. Moreover, improved
systolic function and reduced diastolic function indicates
early ventricular remodeling secondary to obesity and
T2DM in db/db mice.
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